The launch of new first-in-class products is expected to drive growth in the lupus market at a compound annual growth rate of 10.6%, according to a report by GlobalData.

Titled ‘PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2025’, the report covers the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Including systemic lupus erythematosus (SLE) and lupus nephritis (LN), the lupus market is expected to be driven by the launch first-in-class pipeline drugs anifrolumab, Orencia (abatacept), and Lupuzor, as well as therapeutic drugs, atacicept, blisibimod, and voclosporin.

AstraZeneca’s anifrolumab is an anti-interferon monoclonal antibody (mAb) expected to dominate the lupus market with demonstrated efficacy in patients with cutaneous and articular involvement. The drug is expected to acquire a 75% share of all SLE patients and also drive the development of other anti-interferon mAbs.

"The report also projects the increase in prevalence of lupus across the 7MM and better awareness of the disease to result in the rise in uptake of lupus medications."

The report also projects the increase in prevalence of lupus across the 7MM and better awareness of the disease to result in the rise in uptake of lupus medications.

See Also:

GlobalData healthcare analyst Sebastian S. Gehrke states that anti-malarials, steroids, and other immunosuppressive agents will continue to dominate the market. Gehrke also anticipates biologics to witness an increase in uptake and strengthen their dominance in the market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A large share of patients still lack access to efficient medication despite the launch of new pipeline drugs. The existing medications available in the market possess undesirable safety profiles. In addition, poor understanding of the etiology of lupus has resulted in a high unmet need of patients.